Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25November 21, 2025 4:15 PM EST | Source: Reportable, Inc.Dallas, Texas--(Newsfile Corp. - November 21, 2025) - OS Therapies Inc. (NYSE American: OSTX): Stonegate Capital Partners updates their coverage on OS Therapies Inc. (NYSE American: OSTX). OS Therapies advanced key clinical, regulatory, and commercial milestones in 3Q25 as it moves closer to bringing OST-HER2 to patients with recurrent, fully resected, pulmonary m ...

In my article from October, "My Top 5 Biotech Stocks Big Pharma Could Buy Next," I mentioned how Phathom Pharmaceutical's ( PHAT ) Voquezna and Voquezna Triple Pak is actively capturing share in the U.S. GERD and H. pylori infection treatment markets.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, ...

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 21, 2025 2:16 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...

PresentationDomenica MartoranaAssociate Director of Global Investor Relations Welcome to our next QIAGEN Deep Dive. Today, we will focus on our Sample Technologies business. The sample is the starting point of every discovery of every molecular workflow. Preparing a sample and getting the DNA and RNA out of it is the foundation of all molecular testing, and it's where QIAGEN began. Sample Technologies are at the core of what we do. And today, we will show you what makes this business so exciting, what makes ...

A month has gone by since the last earnings report for Viking Therapeutics, Inc. (VKTX) . Shares have added about 1% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Viking Therapeutics due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Viking Therapeutics, Inc. before we dive into how investors and analysts have reacted as of late ...

Contineum Therapeutics, Inc. (NASDAQ:CTNM) on Thursday shared topline data from its Phase 2 VISTA trial of PIPE-307, an M1 receptor antagonist for relapsing-remitting multiple sclerosis (RRMS).RRMS is the most common type of MS, characterized by unpredictable periods of new or worsening symptoms (relapses) followed by periods of recovery (remissions).MS is an autoimmune disease where the immune system attacks the myelin sheath, the protective covering of nerve fibers in the brain and spinal cord.The trial d ...

Core Insights - The integration of Artificial Intelligence (AI) in the U.S. healthcare industry has significantly increased, with 79% of healthcare organizations utilizing AI technology as of March 2024 [1] Group 1: AI Integration in Healthcare - AI is being integrated across various industries, including healthcare, with notable partnerships between pharmaceutical companies and AI tech firms [2] - Collaborations are expected to accelerate drug discovery, streamline clinical trials, and automate administrative tasks, potentially saving billions and enhancing operational efficiency [3][9] Group 2: Notable Pharma-Tech Collaborations - Eli Lilly is partnering with NVIDIA to create an "AI Factory" aimed at accelerating drug discovery by compressing decades of research into accessible intelligence [5] - Johnson & Johnson has been collaborating with NVIDIA to enhance surgical decision-making and training through real-time AI analysis in operating rooms [6] - AbbVie utilizes Palantir's Foundry platform for data management, which unifies data sources and streamlines clinical trial data, boosting operational efficiency [8] Group 3: Market Potential and Investment Opportunities - The global AI in healthcare market is projected to grow from $26.57 billion in 2024 to $505.59 billion by 2033, with a CAGR of 38.81% [10] - Vanguard Health Care ETF (VHT) has assets worth $16.2 billion, with significant weightage in Eli Lilly, AbbVie, and Johnson & Johnson, and has surged 12.3% year to date [11] - Health Care Select Sector SPDR ETF (XLV) has assets under management of $39.01 billion, also featuring major pharmaceutical companies, and has increased by 11.6% year to date [12][13]

Key Takeaways Intellia stock plunged after the FDA placed a clinical hold on phase III studies of nex-z.The setback paused milestone guidance as Intellia works with regulators on next steps.NTLA eyes mid-2026 data for lonvo-z, which could become a key catalyst for the stock.Shares of Intellia Therapeutics (NTLA) have witnessed a sharp decline in the past month, primarily due to a regulatory setback faced with one of its lead in vivo candidates, nex-z (formerly known as NTLA-2001), as well as the mixed third ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Nov. 21 ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). As detailed below, the complaint alleges that the Company and its e ...